Global Acute Migraine Drugs Market Size By Treatment (Preventive, Pain Relieving), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

Acute Migraine Drugs Market Size And Forecast

Acute Migraine Drugs Market size was valued at USD 4.17 Billion in 2021 and is projected to reach USD 8.75 Billion by 2030, growing at a CAGR of 8.58 % from 2023 to 2030.

A migraine headache is characterized by strong throbbing pain or a pulsating feeling on one side of the brain. It is often accompanied by nausea, vomiting, and excessive light and sound sensitivity. Migraine episodes may persist for hours or days, and the pain can be severe enough to interfere with everyday tasks. The Global Acute Migraine Drugs Market is expected to rise due to the rising demand for migraine treatment, increasing demand from pharmaceutical companies, clinics, and medical research laboratories, and the growing number of manufacturers.

Global Acute Migraine Drugs Market Definition

Migraine is a neurological medical disease in which a person has a throbbing and painful headache. Symptoms such as vomiting, numbness, nausea, and trouble speaking may be present. A warning sensation known as an aura develops before or with the headache in some individuals. Visual disturbances, such as flashes of light or blind patches, or other disturbances, such as tingling on one side of the face, arm, or leg, and trouble speaking, may all be signs of an aura.

Migraine is a neurological disorder that causes headaches, nausea, inability to smell, increased sensitivity to sound and light, and numbness, among other symptoms. These headaches start on one side of the head and last for a multitude of times and intensities. There are around 150 distinct types of headaches, divided into two groupsprimary and secondary headaches. A migraine is a primary headache, meaning it isn’t caused by another medical problem. Primary headache disorders are clinical diagnoses, which means they can’t be diagnosed with a blood test or an imaging scan. A subsequent headache is a sign of another problem.

Ergot alkaloids, triptans, and other migraine treatments are available on the Acute Migraine Drugs Market. Migraines are also thought to be genetically connected and may affect persons of all ages. Stress, alcohol, hormone fluctuations, and food allergies are all examples of extrinsic variables that might cause a throbbing headache. Migraines are often self-limiting. Certain severe instances, however, need the use of pharmaceuticals such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and antipsychotics, among others. The younger generation has been predisposed to migraine discomfort due to the increasing adoption of a sedentary lifestyle.

Global Acute Migraine Drugs Market Overview

The Global Acute Migraine Drugs Market is expected to increase due to the rising prevalence of neurological disorders, increasing work pressure, high alcohol consumption, changes in lifestyles, and increasing demand for quality drugs. Furthermore, the rise in the female population and increased awareness among patients about migraine prevention and treatment, growing knowledge of migraine and treatment choices, and increasing R&D investment, which has resulted in a large pipeline of medicines, are major drivers expected to increase the market’s growth. However, a lack of proper diagnosis and undiagnosed cases, drug side effects, strict government rules, and a rising preference for alternative therapies are major restraints to the market’s growth.

Global Acute Migraine Drugs Market Segmentation Analysis

The Global Acute Migraine Drugs Market is Segmented on the basis of Treatment, Route of Administration, Distribution Channel, And Geography.

Acute Migraine Drugs Market, By Treatment

• Preventive
• Pain Relieving

Based on Treatment, The market is segmented into Preventive and Pain Relieving. The preventive segment is projected to rise the most during to forecasted period due to the rising need for complete cure treatment, strong evidence of effectiveness, and fewer adverse effects.

Acute Migraine Drugs Market, By Route of Administration

• Oral
• Injectable
• Nasal Sprays
• Others

Based on Route of Administration, The market is segmented into Oral, Injectable, Nasal Sprays, and Others. Oral drugs are projected to rise the most during to forecasted period due to effectiveness, ease to take, and good absorption in the blood.

Acute Migraine Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Distribution Channel, The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are projected to rise the most during to forecasted period due to an increased number of neurological diseases, a rising number of patients, and the availability of drugs.

Acute Migraine Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Geography, The Global Acute Migraine Drugs Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The Global Acute Migraine Drugs Market in the North American region is expected to increase the most compared to other regions during the projected period due to the increasing adoption of novel therapeutics, a large patient base, a rise in demand for better healthcare facilities, and improvements in healthcare infrastructure.

Key Players

The “Global Acute Migraine Drugs Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Endo International, Allergan, Impax Laboratories, Glaxo Smith Kline, Astellas, Amgen, Bayer, AstraZeneca, Dr. Reddy’s Laboratories, Eli Lilly and Company, and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In February 2022, Biohaven Pharmaceutical Company Ltd. and Pfizer Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist.
• In January 2022, Elyxyb (celecoxib oral solution), a fast-acting liquid, was introduced by BioDelivery Sciences. It is one of the first FDA-approved ready-to-use oral solutions for adults with or without aura in the acute treatment of migraine.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Acute Migraine Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the Global Acute Migraine Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research